1. Home
  2. Companies
  3. MYX
  4. Material Events

Mayne Pharma (ASX:MYX) — Material Events

ASX:MYX · 21 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 1 article Significant 12 articles Notable 8 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
12
FIRB Blocks Cosette’s Bid for Mayne Pharma, Scheme Faces CollapseHigh
FIRB objects to Cosette's acquisition of Mayne Pharma; scheme unlikely to proceed
21 Nov 2025 ·Scheme Update ·Unexpected ·85
Mayne Pharma Launches Legal Battle Over Failed Cosette AcquisitionHigh
Mayne Pharma sues Cosette and partners for damages over terminated acquisition deal
18 Feb 2026 ·Litigation Announcement ·Unexpected ·85
Takeovers Panel Orders Cosette to Restrict Closure of Mayne Pharma’s Salisbury Site Amid Scheme DisputeHigh
Takeovers Panel Orders Cosette to Restrict Closure of Mayne Pharma's Salisbury Site Amid Scheme Dispute
19 Nov 2025 ·Declaration of Unacceptable Circumstances and Orders ·Unexpected ·85
Mayne Pharma’s DistributeRx Launch Drives Prescription Growth and Cash SurgeMedium
Mayne Pharma posts 1% revenue growth and strong cash flow with DistributeRx launch exceeding forecasts
29 Apr 2026 ·Quarterly Financial Results ·85
Mayne Pharma Sets 2032 Generic Entry Date for IMVEXXYHigh
Mayne Pharma settles IMVEXXY patent litigation with Sun Pharma, setting generic entry for 2032
30 Sept 2026 ·Patent Litigation Settlement ·82
Mayne Pharma clears final IMVEXXY patent dispute with TevaHigh
Mayne Pharma settles Teva IMVEXXY patent litigation with generic entry set for 2032
16 Oct 2026 ·Patent Litigation Settlement ·82
Mayne Pharma Doubles EBITDA in FY25, Launches New Dermatology ProductsMedium
Mayne Pharma reports strong FY25 earnings growth, launches new dermatology products, and outlines FY26 growth strategy
29 Jan 2026 ·Annual General Meeting Presentation ·80
Mayne Pharma Faces Uncertain Appeal in Cosette Acquisition BattleMedium
Mayne Pharma faces appeal in acquisition dispute with Cosette Pharmaceuticals
10 Nov 2025 ·Legal Proceedings Update ·80
Treasurer Flags National Interest Risks Over Mayne Pharma DealHigh
Treasurer raises national interest concerns over Cosette's acquisition of Mayne Pharma citing potential closure of Adelaide site
31 Oct 2025 ·Scheme Update ·Unexpected ·80
Mayne Pharma Faces Key FIRB Deadline Amid Financing Uncertainty for Cosette DealMedium
Mayne Pharma updates on FIRB approval extension and financing risks for Cosette acquisition
18 Nov 2025 ·Scheme Update ·75
Mayne Pharma’s Women’s Health Growth Offsets Dermatology Price PressuresMedium
Mayne Pharma posts mixed FY26 start with strong Women’s Health growth, Dermatology margin gains, and strategic review underway
22 Dec 2025 ·Market Update ·75
Mayne Pharma Rebukes Cosette’s Attempted Scheme Termination Over FIRB HurdleHigh
Mayne Pharma rejects Cosette's purported termination of Scheme Implementation Deed over FIRB condition dispute
10 Dec 2025 ·ASX Announcement ·Unexpected ·75
Notable Score 50–74
8
Mayne Pharma Secures $14.4M Legal Costs from Cosette After Court RulingMedium
Mayne Pharma receives $14.4 million legal costs payment from Cosette Pharmaceuticals following court ruling
5 June 2026 ·Legal Proceedings Update ·70
Mayne Pharma Elevates CFO Aaron Gray to CEO in Smooth Leadership ShiftMedium
Mayne Pharma CEO steps down; CFO Aaron Gray appointed new CEO in planned leadership transition
23 Feb 2026 ·Management Change ·70
Mayne Pharma Awaits FIRB Nod Ahead of Crucial Court HearingMedium
Mayne Pharma updates on FIRB approval and court hearing for acquisition scheme
4 Nov 2025 ·Scheme Update ·70
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.